Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Oral Oncology|August 28, 2023
Radiation therapy for cT1-2 carcinoma of the palatine tonsil diagnosed via a simple tonsillectomy: Dosimetry and patterns of care in the IMRT eraMatthew C Ward, Michelle L Wallander, Jeffrey G Kuremsky, et al.
JAMA Otolaryngology-- Head & Neck Surgery|August 8, 2024
Planned Dental Extractions After Radiation TherapyMatthew C Ward, Cathleen M Petersen, Jenene Noll, et al.
British Journal of Clinical Pharmacology|April 25, 2015
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and allelesDaniel L Hertz, Anna C Snavely, Howard L McLeod, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2024
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, et al.
The Oncologist|May 27, 2016
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing ToxicityDaniel L Hertz, Allison Deal, Joseph G Ibrahim, et al.
Cancer|March 14, 2020
Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysisJames R Broughman, David D Xiong, Benjamin J Moeller, et al.
Oral Oncology|October 31, 2020
Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial designChristopher W Fleming, Matthew C Ward, Neil M Woody, et al.
JCO Precision Oncology|December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) FusionsTejas Patil, Jessica J Lin, Parneet K Cheema, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Pageof 2